Orthocell Limited (ASX:OCC), PolyNovo Limited (ASX:PNV) and Aroa Biosurgery Limited (ASX:ARX) operate across different areas of regenerative medicine and tissue repair. Orthocell develops collagen-based devices led by the Remplir nerve repair platform, PolyNovo manufactures biodegradable synthetic scaffolds for burns and complex wounds, while Aroa develops soft-tissue regeneration products based on ovine extracellular matrix.

Their 2026 disclosures show that commercial adoption is now as important as product development. Orthocell is expanding Remplir across US hospitals, PolyNovo is seeking further growth from NovoSorb BTM and the newer MTX format, while Aroa is increasing Investment in direct sales as it expands Myriad and prepares Symphony for a changing US reimbursement environment.

2026 Regenerative Medicine Context

Regenerative medicine companies selling into hospitals face a different commercial process from conventional consumer healthcare businesses. Regulatory clearance establishes the right to market a product, but hospitals still need to approve purchasing, surgeons need to adopt the technology and reimbursement must support its use.

This makes institutional adoption an important operating measure. Product uptake can be gradual because individual hospitals may require value analysis committee approval before a new device is added to purchasing systems.

The Economics of the sales channel also matter. Direct sales teams provide greater control over relationships with surgeons and hospitals but require considerable upfront investment. Distributor networks can extend coverage more quickly, although the manufacturer gives up some Margin and has less direct control over selling activity.

US reimbursement for wound-care products has also been changing during 2026, adding another variable for companies exposed to skin substitutes and related products. Product economics increasingly depend on clinical outcomes, Supply costs and the ability to operate effectively under revised reimbursement structures.

Orthocell Limited (ASX:OCC)

Business Profile

Orthocell develops regenerative medicine products using its proprietary collagen-based SMRT platform.

Its lead product is Remplir, a resorbable collagen nerve wrap designed to support peripheral nerve repair. The device can be used to connect damaged nerves, protect nerves following decompression procedures and support other nerve-repair applications.

Orthocell also markets Striate+, a collagen membrane used in dental bone and tissue regeneration.

The company manufactures its products in Western Australia and is increasingly focused on expanding international commercial adoption.

FY2026 Commercial Progress

Orthocell reported FY2026 Revenue of AUD 13.2 million, supported by continued adoption across its existing markets and the expansion of Remplir.

The June 2026 quarter produced record quarterly revenue of AUD 3.8 million, providing an indication of the sales run rate entering FY2027.

The US market remains the most important expansion opportunity. During the June quarter, US Remplir revenue reached AUD 0.33 million from 119 units.

The number of US hospitals purchasing Remplir increased to 70, while the number of surgeons using the product reached 76.

Hospital value analysis committee approvals increased to 44, covering 151 hospitals, with a further 64 applications pending at the end of June.

These measures are important because commercial expansion depends on converting regulatory clearance and surgeon interest into recurring hospital purchasing.

Manufacturing Capacity

Orthocell is also increasing Manufacturing capacity to support future commercial growth.

Construction began during June 2026 on an expanded Facility requiring approximately AUD 5 million to AUD 5.5 million of investment.

The project is designed to increase device manufacturing capacity by around four times existing levels.

Scaling manufacturing ahead of Demand creates some execution risk, but it also provides capacity if hospital adoption accelerates across the United States and other markets.

Risks

Hospital adoption is one of Orthocell's main risks. Regulatory clearance does not ensure that individual hospitals will approve or purchase the product.

The company is also still refining its US distributor network, which means national sales infrastructure is not yet complete.

Funding remains relevant while Orthocell operates at a loss and invests in manufacturing capacity.

A slower-than-expected US rollout could extend the period before revenue covers the expanding commercial cost base.

What Investors May Monitor Through the Rest of 2026

Orthocell Limited (ASX:OCC) may remain focused on converting pending US hospital approvals into active purchasing accounts.

The number of surgeons regularly using Remplir and the number of procedures performed will provide additional measures of commercial progress.

Investors may also monitor completion of the manufacturing expansion and further progress toward broader distribution coverage in the United States and other international markets.

PolyNovo Limited (ASX:PNV)

Business Profile

PolyNovo develops and manufactures biodegradable synthetic medical devices using its NovoSorb polymer technology.

Its main product, NovoSorb BTM, is a synthetic dermal matrix used in the treatment of burns, trauma, complex wounds and reconstructive procedures.

The product provides a scaffold through which the patient's own tissue can regenerate before the sealing membrane is removed and further wound closure is undertaken.

PolyNovo has also developed NovoSorb MTX, a more flexible format intended to broaden the applications of the technology.

FY2026 Performance

PolyNovo reported FY2026 revenue of approximately AUD 143.7 million.

Operating income was approximately AUD 10.5 million, while net profit after tax was around AUD 7.3 million.

The company therefore remains profitable while continuing to invest in commercial expansion, clinical education and product development.

NovoSorb BTM remains the central revenue-generating product, although the expansion of MTX creates an opportunity to increase revenue through the existing hospital and surgeon network.

Risks

Growth execution is a central risk. PolyNovo needs to continue increasing revenue while managing commercial and manufacturing costs.

The company also remains substantially dependent on the NovoSorb technology platform, creating product concentration risk.

Regulatory work on additional indications can require considerable investment without guaranteed approval.

Manufacturing scale-up introduces further quality and supply-chain requirements as product volumes increase.

What Investors May Monitor Through the Rest of 2026

PolyNovo Limited (ASX:PNV) may remain focused on the pace of NovoSorb BTM sales and initial adoption of MTX.

Investors may also monitor manufacturing capacity, hospital penetration and further clinical use across burn and reconstructive procedures.

Updates relating to the full-thickness burns regulatory programme would provide another indication of the company's longer-term expansion opportunities.

Aroa Biosurgery Limited (ASX:ARX)

Business Profile

Aroa Biosurgery develops soft-tissue regeneration products using ovine forestomach matrix, a decellularised extracellular matrix derived from New Zealand sheep.

Its product families include Myriad for complex soft-tissue reconstruction, Symphony for chronic wounds and Endoform for wound care.

Aroa also manufactures OviTex products distributed by TELA Bio in North America and Europe.

The company reports its financial statements in NZD and operates with a combination of direct commercial sales and partner-led distribution.

FY2026 Performance

For the year ended 31 March 2026, Aroa reported revenue of NZD 103.9 million.

Myriad contributed NZD 49.6 million, while sales to TELA Bio generated NZD 42.8 million.

Product gross margin reached 85.5%, reflecting the economics of specialised regenerative medicine products once they have been manufactured.

Normalised EBITDA was NZD 12.6 million and net profit after tax reached NZD 4.7 million.

Operating cash flow was NZD 10.5 million.

Aroa ended the financial year with NZD 27.1 million of cash and term deposits and no debt.

FY2027 Outlook

Aroa has guided to FY2027 revenue of NZD 115 million to NZD 125 million on a constant-currency basis.

Normalised EBITDA is expected to be between NZD 8 million and NZD 11 million.

The lower EBITDA range despite expected revenue growth reflects approximately NZD 9 million of additional investment.

Around NZD 5 million is expected to support Myriad expansion and approximately NZD 4 million is directed toward Symphony launch infrastructure.

The strategy therefore deliberately prioritises future commercial capacity over near-term margin expansion.

Risks

Customer concentration is one of Aroa's clearest risks because TELA Bio represents a substantial share of revenue.

If partner sales remain subdued for longer than expected, Aroa's direct businesses need to grow sufficiently to offset the effect.

Investment in sales capacity also creates execution risk. A slower Symphony launch could leave Aroa carrying a larger commercial cost base without the expected revenue contribution.

Foreign exchange remains relevant because Aroa reports in NZD while a substantial part of its Business is generated in international markets.

What Investors May Monitor Through the Rest of 2026

Aroa Biosurgery Limited (ASX:ARX) may remain focused on direct Myriad sales and the initial commercial build-out for Symphony.

Investors may monitor whether hospital contracting changes under the revised US reimbursement environment improve access for Symphony and related products.

The first-half FY2027 result, expected by the end of November 2026, should provide a clearer indication of progress toward revenue guidance and the effect of increased commercial investment.

Risks to Watch

Orthocell faces hospital-adoption, distribution and funding risks. Remplir has regulatory clearance and a growing account base, but US sales still need to expand materially before the commercial operation reaches scale.

PolyNovo faces execution, manufacturing and regulatory risks. The company is already profitable, but continued growth depends on deeper hospital adoption and successful development of additional applications for NovoSorb.

Aroa faces customer-concentration, reimbursement and commercial-investment risks. The company is deliberately increasing spending on direct growth initiatives while expecting partner revenue to remain relatively stable.

Across all three companies, hospital purchasing decisions and surgeon adoption can move more slowly than regulatory milestones, making commercial execution a continuing sector-wide variable.

Outlook Through the Rest of 2026

Orthocell enters FY2027 after reporting AUD 13.2 million of FY2026 revenue and approximately AUD 44.1 million of available funds. US hospital approvals, surgeon adoption and manufacturing expansion will remain the main operational themes.

PolyNovo enters FY2027 with approximately AUD 143.7 million of FY2026 revenue and continued profitability. NovoSorb BTM growth, MTX adoption and regulatory development around burns remain central to the outlook.

Aroa enters FY2027 after generating NZD 103.9 million of revenue and moving into profitability. The group is increasing commercial investment as Myriad expands and Symphony approaches a larger US opportunity.

The three businesses therefore enter FY2027 with different priorities: Orthocell is focused on scaling Remplir in the United States, PolyNovo on extending an established synthetic scaffold platform, and Aroa on direct sales expansion and navigating revised wound-care reimbursement.